Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Mathai

Showing results (191-200 of 217) with videos related to

Pageof 22
Sort By:
Pulmonary Circulation|December 19, 2017
The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking studyTakahiro Sato, Bharath Ambale-Venkatesh, Joao A C Lima, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2015
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial HypertensionPaul M Hassoun, Roham T Zamanian, Rachel Damico, et al.
American Journal of Respiratory and Critical Care Medicine|May 13, 2022
Impact of Sex and Gender on Autoimmune Lung Disease: Opportunities for Future Research: NHLBI Working Group ReportElizabeth R Volkmann, Jill Siegfried, Tim Lahm, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2018
Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research StatementTim Lahm, Ivor S Douglas, Stephen L Archer, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Resolving Diagnostic Discordance in Group 2 Pulmonary Hypertension Through Staged Physiologic Testing: Insights From PVDOMICSFranz P Rischard, Mateo Mendoza, Michael Insel, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertensionRachel Damico, Todd M Kolb, Lidenys Valera, et al.
European Heart Journal. Cardiovascular Imaging|June 7, 2021
Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experienceChristine L Jellis, Margaret M Park, Aiden Abidov, et al.
Circulation|February 13, 2026
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary HypertensionYogesh N V Reddy, Robert P Frantz, William R Miranda, et al.
Annals of the American Thoracic Society|July 18, 2025
Ground Glass Opacities in Pulmonary Arterial Hypertension-Results from the PVDOMICS StudyDivya Padmanabhan Menon, Robert P Frantz, Benjamin R Gochanour, et al.
Pageof 22

Showing results (191-200 of 217) with videos related to

Sort By:
Pageof 22
Pulmonary Circulation|December 19, 2017
The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking studyTakahiro Sato, Bharath Ambale-Venkatesh, Joao A C Lima, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2015
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial HypertensionPaul M Hassoun, Roham T Zamanian, Rachel Damico, et al.
American Journal of Respiratory and Critical Care Medicine|May 13, 2022
Impact of Sex and Gender on Autoimmune Lung Disease: Opportunities for Future Research: NHLBI Working Group ReportElizabeth R Volkmann, Jill Siegfried, Tim Lahm, et al.
Pulmonary Circulation|May 6, 2022
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguatFranck F Rahaghi, Vijay P Balasubramanian, Robert C Bourge, et al.
American Journal of Respiratory and Critical Care Medicine|August 16, 2018
Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research StatementTim Lahm, Ivor S Douglas, Stephen L Archer, et al.
Medrxiv : the Preprint Server for Health Sciences|June 22, 2026
Resolving Diagnostic Discordance in Group 2 Pulmonary Hypertension Through Staged Physiologic Testing: Insights From PVDOMICSFranz P Rischard, Mateo Mendoza, Michael Insel, et al.
American Journal of Respiratory and Critical Care Medicine|December 10, 2014
Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertensionRachel Damico, Todd M Kolb, Lidenys Valera, et al.
European Heart Journal. Cardiovascular Imaging|June 7, 2021
Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experienceChristine L Jellis, Margaret M Park, Aiden Abidov, et al.
Circulation|February 13, 2026
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary HypertensionYogesh N V Reddy, Robert P Frantz, William R Miranda, et al.
Annals of the American Thoracic Society|July 18, 2025
Ground Glass Opacities in Pulmonary Arterial Hypertension-Results from the PVDOMICS StudyDivya Padmanabhan Menon, Robert P Frantz, Benjamin R Gochanour, et al.
Pageof 22